INDP vs. QTTB, BIVI, PLUR, SNYR, BFRG, IXHL, RLYB, PMN, CVM, and MRNS
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Q32 Bio (QTTB), BioVie (BIVI), Pluri (PLUR), Synergy CHC Corp. (Uplisting) (SNYR), Bullfrog AI (BFRG), Incannex Healthcare (IXHL), Rallybio (RLYB), ProMIS Neurosciences (PMN), CEL-SCI (CVM), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry.
Indaptus Therapeutics vs.
Q32 Bio (NASDAQ:QTTB) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
In the previous week, Q32 Bio's average media sentiment score of 0.79 beat Indaptus Therapeutics' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.
Q32 Bio has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 16.1% of Q32 Bio shares are held by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Q32 Bio currently has a consensus price target of $24.86, suggesting a potential upside of 867.20%. Indaptus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 962.50%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Indaptus Therapeutics is more favorable than Q32 Bio.
Indaptus Therapeutics received 1 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 66.67% of users gave Q32 Bio an outperform vote.
Indaptus Therapeutics has higher revenue and earnings than Q32 Bio. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
Q32 Bio's return on equity of -146.18% beat Indaptus Therapeutics' return on equity.
Summary
Indaptus Therapeutics beats Q32 Bio on 9 of the 14 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:INDP) was last updated on 2/22/2025 by MarketBeat.com Staff
